CR20160186A - Anticuerpos anti-cd38 específicos para tratar cánceres humanos - Google Patents
Anticuerpos anti-cd38 específicos para tratar cánceres humanosInfo
- Publication number
- CR20160186A CR20160186A CR20160186A CR20160186A CR20160186A CR 20160186 A CR20160186 A CR 20160186A CR 20160186 A CR20160186 A CR 20160186A CR 20160186 A CR20160186 A CR 20160186A CR 20160186 A CR20160186 A CR 20160186A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibody
- medicament
- specific antibodies
- human cancer
- treat human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898309P | 2013-10-31 | 2013-10-31 | |
| EP14306220 | 2014-07-31 | ||
| PCT/US2014/063380 WO2015066450A1 (en) | 2013-10-31 | 2014-10-31 | Specific anti-cd38 antibodies for treating human cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160186A true CR20160186A (es) | 2016-06-13 |
Family
ID=51266255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160186A CR20160186A (es) | 2013-10-31 | 2016-04-21 | Anticuerpos anti-cd38 específicos para tratar cánceres humanos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150118251A1 (enExample) |
| EP (2) | EP3063173B1 (enExample) |
| JP (3) | JP2016536314A (enExample) |
| KR (1) | KR20160077155A (enExample) |
| CN (1) | CN106103481A (enExample) |
| AU (1) | AU2014342103B2 (enExample) |
| BR (1) | BR112016009403A2 (enExample) |
| CA (1) | CA2927099A1 (enExample) |
| CR (1) | CR20160186A (enExample) |
| EA (1) | EA035098B1 (enExample) |
| IL (1) | IL245196B (enExample) |
| MA (2) | MA44560B2 (enExample) |
| MX (1) | MX373301B (enExample) |
| NZ (1) | NZ719784A (enExample) |
| PL (1) | PL3063173T3 (enExample) |
| PT (1) | PT3063173T (enExample) |
| SG (2) | SG11201603088RA (enExample) |
| TN (1) | TN2016000142A1 (enExample) |
| TW (1) | TW201522378A (enExample) |
| WO (1) | WO2015066450A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| JP7160533B2 (ja) * | 2015-05-13 | 2022-10-25 | モルフォシス・アーゲー | 多発性骨髄腫（ｍｍ）の処置 |
| CA2986594C (en) * | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| HUE051246T2 (hu) | 2015-05-30 | 2021-03-01 | Molecular Templates Inc | Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák |
| WO2016201337A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| CN108699161B (zh) | 2016-03-04 | 2022-06-03 | 莫佛塞斯公司 | 多发性骨髓瘤中m-蛋白应答的临床评估 |
| CN109641049B (zh) | 2016-06-21 | 2023-07-07 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3484923A1 (en) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| MY200988A (en) | 2016-09-14 | 2024-01-27 | Teneobio Inc | CD3 Binding Antibodies |
| KR102745676B1 (ko) | 2016-12-21 | 2024-12-24 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| WO2018237006A1 (en) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | Anti-bcma heavy chain-only antibodies |
| IL312322B2 (en) | 2017-06-20 | 2026-05-01 | Teneobio Inc | Antibodies against BCMA containing only heavy chains |
| WO2019031444A1 (ja) * | 2017-08-07 | 2019-02-14 | 国立大学法人九州大学 | 細胞集団における特異的結合物質の占有率を測定する方法 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| RU2020112490A (ru) * | 2017-09-13 | 2021-10-13 | Тенеобио, Инк. | Антитела из тяжелых цепей, связывающиеся с эктоферментами |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| CN111542545A (zh) | 2017-11-03 | 2020-08-14 | 索伦托治疗有限公司 | Cd38定向嵌合抗原受体构建体 |
| US12371506B2 (en) | 2018-01-12 | 2025-07-29 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of anti-CD38 antibodies |
| AU2019244478B2 (en) * | 2018-03-28 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| CA3105333A1 (en) * | 2018-07-10 | 2020-01-16 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| IL317328A (en) | 2018-12-14 | 2025-01-01 | Morphosys Ag | Antibody formulations |
| CA3133419A1 (en) * | 2019-03-21 | 2020-09-24 | Gamida Cell Ltd. | Expansion and use of expanded nk cell fractions suitable for transplantation in combination therapy |
| CR20210500A (es) | 2019-04-05 | 2021-11-05 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al psma |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| JP7665538B2 (ja) | 2019-06-14 | 2025-04-21 | テネオバイオ， インコーポレイテッド | Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体 |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| TW202606756A (zh) | 2019-12-05 | 2026-02-16 | 美商賽諾菲阿凡提斯美國有限責任公司 | 用於皮下投予之抗cd38抗體的調配物 |
| IL293615A (en) * | 2019-12-06 | 2022-08-01 | Sanofi Aventis Us Llc | Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma |
| EP4169949A4 (en) * | 2020-06-23 | 2024-08-21 | Jiangsu Kanion Pharmaceutical Co., Ltd. | ANTI-CD38 ANTIBODY AND ITS USE |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| US20250382378A1 (en) * | 2022-10-31 | 2025-12-18 | Genmab A/S | Cd38 antibodies and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1976950B (zh) * | 2004-02-06 | 2012-08-29 | 莫佛塞斯公司 | 抗cd38人抗体及其用途 |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP1888647A2 (en) * | 2005-05-24 | 2008-02-20 | MorphoSys AG | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
| AU2007302448C1 (en) * | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191841A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| WO2013059885A2 (en) * | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| JP6279065B2 (ja) * | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
-
2014
- 2014-10-31 EP EP14799089.9A patent/EP3063173B1/en active Active
- 2014-10-31 CN CN201480071448.0A patent/CN106103481A/zh active Pending
- 2014-10-31 PT PT147990899T patent/PT3063173T/pt unknown
- 2014-10-31 CA CA2927099A patent/CA2927099A1/en not_active Abandoned
- 2014-10-31 EA EA201690905A patent/EA035098B1/ru not_active IP Right Cessation
- 2014-10-31 BR BR112016009403A patent/BR112016009403A2/pt not_active Application Discontinuation
- 2014-10-31 NZ NZ719784A patent/NZ719784A/en unknown
- 2014-10-31 TW TW103137932A patent/TW201522378A/zh unknown
- 2014-10-31 JP JP2016527374A patent/JP2016536314A/ja active Pending
- 2014-10-31 SG SG11201603088RA patent/SG11201603088RA/en unknown
- 2014-10-31 PL PL14799089T patent/PL3063173T3/pl unknown
- 2014-10-31 SG SG10201803288RA patent/SG10201803288RA/en unknown
- 2014-10-31 US US14/529,719 patent/US20150118251A1/en not_active Abandoned
- 2014-10-31 TN TN2016000142A patent/TN2016000142A1/en unknown
- 2014-10-31 MX MX2016005666A patent/MX373301B/es active IP Right Grant
- 2014-10-31 MA MA44560A patent/MA44560B2/fr unknown
- 2014-10-31 WO PCT/US2014/063380 patent/WO2015066450A1/en not_active Ceased
- 2014-10-31 MA MA39070A patent/MA39070A1/fr unknown
- 2014-10-31 KR KR1020167013974A patent/KR20160077155A/ko not_active Ceased
- 2014-10-31 EP EP20188077.0A patent/EP3805266A1/en not_active Withdrawn
- 2014-10-31 AU AU2014342103A patent/AU2014342103B2/en active Active
-
2016
- 2016-04-19 IL IL245196A patent/IL245196B/en active IP Right Grant
- 2016-04-21 CR CR20160186A patent/CR20160186A/es unknown
-
2017
- 2017-04-05 US US15/479,500 patent/US20180022814A1/en not_active Abandoned
-
2023
- 2023-05-24 JP JP2023085105A patent/JP2023109927A/ja active Pending
-
2025
- 2025-05-07 JP JP2025077126A patent/JP2025139586A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3063173T3 (pl) | 2021-01-11 |
| EA201690905A1 (ru) | 2016-08-31 |
| EP3805266A1 (en) | 2021-04-14 |
| IL245196A0 (en) | 2016-06-30 |
| CN106103481A (zh) | 2016-11-09 |
| TW201522378A (zh) | 2015-06-16 |
| MX373301B (es) | 2020-04-24 |
| MA44560B2 (fr) | 2021-01-29 |
| SG10201803288RA (en) | 2018-05-30 |
| AU2014342103B2 (en) | 2020-06-04 |
| MA44560A1 (fr) | 2019-09-30 |
| US20180022814A1 (en) | 2018-01-25 |
| MX2016005666A (es) | 2016-07-14 |
| CA2927099A1 (en) | 2015-05-07 |
| PT3063173T (pt) | 2020-10-20 |
| NZ719784A (en) | 2022-02-25 |
| BR112016009403A2 (pt) | 2017-09-19 |
| IL245196B (en) | 2021-04-29 |
| EA035098B1 (ru) | 2020-04-27 |
| MA44560B1 (fr) | 2020-06-30 |
| SG11201603088RA (en) | 2016-05-30 |
| JP2016536314A (ja) | 2016-11-24 |
| KR20160077155A (ko) | 2016-07-01 |
| EP3063173B1 (en) | 2020-07-29 |
| TN2016000142A1 (en) | 2017-10-06 |
| JP2023109927A (ja) | 2023-08-08 |
| EP3063173A1 (en) | 2016-09-07 |
| MA39070A1 (fr) | 2017-11-30 |
| WO2015066450A1 (en) | 2015-05-07 |
| AU2014342103A1 (en) | 2016-05-26 |
| US20150118251A1 (en) | 2015-04-30 |
| JP2025139586A (ja) | 2025-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016005666A (es) | Anticuerpos anti-cd38 especificos para tratar canceres humanos. | |
| MX2015013355A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| EA201691747A1 (ru) | Варианты комбинированной терапии с антителами анти-cd38 | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| RU2016122232A (ru) | Комбинированная терапия на основе антитела к cd20 и ингибитора втк | |
| SV2018005682A (es) | Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana | |
| PH12016500677A1 (en) | Specific anti-cd38 antibodies for treating human cancers | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| MX380557B (es) | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). | |
| MX2020004516A (es) | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2021008738A (es) | Regimenes de dosificacion de melflufen para cancer. | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2017001461A (es) | Terapia de combinacion. | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| IN2013MU03118A (enExample) |